AI Decision-Support Tools Streamline Multidisciplinary Oncology Care
New automation tools are aggregating tumor board data and optimizing radiation dose distributions to reduce clinician burnout and accelerate treatment.
Artificial intelligence is being integrated into oncology workflows to enhance multidisciplinary care coordination and treatment planning. Rather than replacing clinicians, these tools are serving as decision-support systems that aggregate complex data to streamline the path to patient consensus.
In the clinical setting, AI is now being used to support tumor boards by automating the aggregation of pathology reports, imaging findings, genomic data, prior treatments, and clinical guidelines. In the realm of radiation oncology, the technology is specifically optimizing treatment planning by generating predictable dose distributions and optimizing beam arrangements. According to CancerNetwork, this automation reduces the need for physics staff to perform iterative manual adjustments, accelerating the technical phase of care.
The Bottleneck in Complex Care
Multidisciplinary tumor boards have long been the gold standard for treating complex cancers, requiring the synchronized input of surgeons, medical and radiation oncologists, pathologists, and radiologists. However, the process has historically been hindered by significant bottlenecks. The manual synthesis of diverse data sets and the repetitive, iterative nature of radiation planning often created administrative delays that slowed the transition from diagnosis to treatment.
Implications for Precision and Access
By reducing the technical and administrative burden of data synthesis, AI allows oncology teams to reach treatment consensus more accurately and rapidly. This shift is intended to return critical time to physicians, allowing for more direct interpersonal engagement with patients. The result is a dual benefit: an increase in the precision of the technical treatment plan and a potential improvement in the overall patient experience through increased physician availability.
Market Growth and Future Outlook
As these tools become embedded in standard care, the financial scale of the infrastructure is growing. Growth Market Reports projects that the AI-driven virtual tumor board platform market will reach an estimated USD 10.76 billion by 2034. Despite this growth, experts emphasize that the technology remains a supplement to human expertise. Dr. Nevine Hanna, MD, MPH, FACRO, DABR, noted that while AI can serve as an effective decision-support tool for tumor boards, "it cannot be the decision maker, per se."